share_log

bluebird bio | 4: Statement of changes in beneficial ownership of securities-Officer Obenshain Andrew

SEC announcement ·  Feb 6 16:13
Summary by Moomoo AI
Andrew Obenshain, President and CEO of bluebird bio, Inc., completed a sale of 1,879 shares of common stock on February 5, 2024. The transaction was carried out in the open market with a sale price of $0.9025 per share, resulting in a total value of approximately $1,695.80. Following the sale, Obenshain's direct holdings in the company amount to 286,093 shares of common stock.
Andrew Obenshain, President and CEO of bluebird bio, Inc., completed a sale of 1,879 shares of common stock on February 5, 2024. The transaction was carried out in the open market with a sale price of $0.9025 per share, resulting in a total value of approximately $1,695.80. Following the sale, Obenshain's direct holdings in the company amount to 286,093 shares of common stock.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more